ArriVent BioPharma’s (AVBP) Buy Rating Reiterated at Guggenheim
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $45.00 price objective on the stock. Guggenheim’s price objective points to a potential upside of 97.37% from the company’s previous close. Other equities […]
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $45.00 price objective on the stock. Guggenheim’s price objective points to a potential upside of 97.37% from the company’s previous close. Other equities […]
